Ligands to the integrin receptor α_vβ₃

Bibliography

• GIANCOTTI FG, RUOSLAHTI E: Integrin signaling. Science (1999) 285(5430):1028–1032.
   PubMed Web of Science ®Google Scholar
• •This paper is a comprehensive review on the function, ligand binding and intracellular signaling of integrins.
   Google Scholar
• VAN DER FLIER A, SONNENBERG A: Function and interactions of integrins. Cell Tissue Res. (2001) 305(3):285–298.
   PubMedGoogle Scholar
• •This paper is a comprehensive review on the function, ligand binding and intracellular signaling of integrins.
   Google Scholar
• DUONG LT, RODAN GA: The role of integrins in osteoclast function. J. Bone Miner. Metab. (1999) 17(1):1–6.
   PubMedGoogle Scholar
• •This paper summarised studies on the role of as,[33 integrins in osteoclast function and report the pharmacological evaluations of various RGD-containing peptides or RGD-mimetics in the inhibition of bone loss.
   Google Scholar
• HORTON MA: Integrin antagonists as inhibitors of bone resorption: implications for treatment. Proc. Nutr. Soc. (2001) 60(2):275–281.
   PubMedGoogle Scholar
• •This paper summarised studies on the role of a,[33 integrins in osteoclast function and report the pharmacological evaluations of various RGD-containing peptides or RGD-mimetics in the inhibition of bone loss.
   Google Scholar
• HUMPHRIES MJ: Integrin structure. Biochein. Soc. Trans. (2000) 28(4):311–339.
   PubMedGoogle Scholar
• •This review discussed the predicted models for integrin structure, issues relating to the mapping of ligand binding sites, and conformation changes in integrin during its activation.
   Google Scholar
• XIONG JP, STEHLE T, ZHANG R et al: Crystal structure of the extracellular segment of integrin avI33 in complex with an Arg-Gly-Asp ligand. Science (2002) 296:151–155.
   PubMed Web of Science ®Google Scholar
• ••This landmark study now enables previousbiochemical studies on integrins to be placed in the context of a tertiary structure and further our understandings on how integrins interact with their ligartds, how ligand binding affects integrin conformation, and how receptor activation is coupled to bidirectional signal propagation. Morever, the crystal structure of this integrin will aid the design of potent and selective inhibitors for avp3.
   Google Scholar
• NERMUT MV, GREEN NM, EASONP, YAMADA SS, YAMADA KM: Electron microscopy and structural model of human fibronectin receptor. EMBO J. (1988) 7(13):4093–4099.
   PubMedGoogle Scholar
• PLOW EF, HAAS TA, ZHANG L, LOFTUS J, SMITH JW: Ligand binding to integrins. j Biol. Chem. (2000) 275(29):21785–21788.
   PubMed Web of Science ®Google Scholar
• •This review discussed the predicted models for integrin structure, issues relating to the mapping of ligand binding sites, and conformation changes in integrin during its activation.
   Google Scholar
• RODAN SB, RODAN GA: Integrin function in osteoclasts. j Endocnirol. (1997) 154:S47–56.
   PubMedGoogle Scholar
• McHUGH KP, HODIVALA-DILKE K, ZHENG MH et al.: Mice lacking 33 integrins are osteosclerotic because of dysfunctional osteoclasts. j Chi]. Invest. (2000) 105(4):433–440.
   PubMed Web of Science ®Google Scholar
• ••This work provided direct evidence for therole of as,[33 integrin in bone resorption in vivo.
   Google Scholar
• NAKAMURA I. TANAKA H., RODAN GA, DUONG LT: Echistatin inhibits the migration of murine prefusion osteoclasts and the formation of multinucleated osteoclast-like cells. Endocrinology (1998) 139(12):5182–5193.
   PubMedGoogle Scholar
• ••The results of this paper supported thehypothesis that inhibition of as,[33 integrin in osteoclasts by a disintegrin results in a reduction in osteoclastic bone resorption efficiency.
   Google Scholar
• ELICEIRI BP, CHERESH DA: Adhesion events in angiogenesis. Curr. Opin. Cell Biol. (2001) 13(5):563–568.
   PubMedGoogle Scholar
• •Summarises evidence to support the role of av integrins during angiogenesis and promoted the development of %,133 antagonists as novel antiangiogenic agents.
   Google Scholar
• SILLETTI S, KESSLER T, GOLDBERG J, BOGER DL, CHERESH DA: Disruption of matrix metalloproteinase 2 binding to integrin a,P3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc. Natl. Acad. Sri. USA (2001) 98(1):119–124.
   PubMed Web of Science ®Google Scholar
• •Summarises evidence to support the role of a,, integrins during angiogenesis and promoted the development of a,,3 antagonists as novel antiangiogenic agents.
   Google Scholar
• ELICEIRI BP, CHERESH DA: Role of ay integrins during angiogenesis. Cancer Am. (2000) 6\(Suppl. 3):S245–249.
   Google Scholar
• •Summarises evidence to support the role of a,, integrins during angiogenesis and promoted the development of a,,3 antagonists as novel antiangiogenic agents.
   Google Scholar
• CARRON CP, MEYER DM, PEGG JA et al.: A peptidomimetic antagonist of the integrin cs,33 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy. Cancer Res. (1998) 58(9):1930–1935.
   PubMed Web of Science ®Google Scholar
• •Summarises evidence to support the role of integrins during angiogenesis and promoted the development of %,133 antagonists as novel antiangiogenic agents.
   Google Scholar
• KERR JS, SLEE AM, MOUSA SA: Small molecule a(v) integrin antagonists: novel anticancer agents. Expert Opin. Investig. Drugs (2000) 9(6):1271–1279.
   PubMed Web of Science ®Google Scholar
• •Summarises evidence to support the role of a,, integrins during angiogenesis and promoted the development of a,,3 antagonists as novel antiangiogenic agents.
   Google Scholar
• MIKECZ K: Vitaxin applied molecular evolution. Cun: Opin. Investig. Drugs (2000) 1(2):199–203.
   PubMedGoogle Scholar
• •Summarises evidence to support the role of a,, integrins during angiogenesis and promoted the development of as,133 antagonists as novel antiangiogenic agents.
   Google Scholar
• BADER BL, RAYBURN H, CROWLEY D, HYNES RO: Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all av integrins. Cell (1998) 95(4):507–519.
   PubMed Web of Science ®Google Scholar
• •Provides genetic evidence that the as, integrins have no role in neovascularisation.
   Google Scholar
• HUANG X, GRIFFITHS M, WU J, FARESE RV Jr., SHEPPARD D: Normal development, wound healing, and adenovirus susceptibility in 135-deficient mice. Mol. Cell. Biol. (2000) 20(3):755–759.
   Google Scholar
• •Provides genetic evidence that the as, integrins have no role in neovascularisation.
   Google Scholar
• REYNOLDS LE, WYDER L, LIVELY JC etal.: Enhanced pathological angiogenesis in mice lacking 33 integrin or 33 and P5 integrins. Nat. Med. (2002) 8(1):27–34.
   Google Scholar
• •Recent report showing that [33/[35-null mice displayed enhanced pathological angiogenesis.
   Google Scholar
• KUMAR S, LI C: Targeting of vasculature in cancer and other angiogenic diseases. Trends Immurrol. (2001) 22(3):129.
   PubMedGoogle Scholar
• •Discussion of the therapeutic potential of a,,3 antagonists in angiogenic diseases other than cancer, such as rheumatoid arthritis, restenosis and ocular diseases.
   Google Scholar
• STUPACK DG, STORGARD CM, CHERESH DA: A role for angiogenesis in rheumatoid arthritis. Biz. j Med. Biol. Res. (1999) 32(5):573–581.
   PubMedGoogle Scholar
• •Discussion of the therapeutic potential of as,[33 antagonists in angiogenic diseases other than cancer, such as rheumatoid arthritis, restenosis and ocular diseases.
   Google Scholar
• STORGARD CM, STUPACK DG, JONCZYK A, GOODMAN SL, FOX RI, CHERESH DA: Decreased angiogenesis and arthritic disease in rabbits treated with an cs,33 antagonist. j Chi]. Invest. (1999) 103(1)47–54.
   Google Scholar
• •Discussion of the therapeutic potential of an.133 antagonists in angiogenic diseases other than cancer, such as rheumatoid arthritis, restenosis and ocular diseases.
   Google Scholar
• MILLER WH, KEENAN RIVI, WILLETTE RN, LARK MW: Identification and in vivo efficacy of small-molecule antagonists of integrin cs,33 (the vitronectin receptor). Drug Discov. Today (2000) 5(9):397–408.
   PubMedGoogle Scholar
• •Discussion of the therapeutic potential of as,[33 antagonists in angiogenic diseases other than cancer, such as rheumatoid arthritis, restenosis and ocular diseases.
   Google Scholar
• SORBERA LA, GRAUL A, CASTANER J: Cilengitide. Drugs Future (2000) 25(7)674–678.
   Google Scholar
• ESKENS 1 DUMEZ H, VERWEIJ J et al.: Phase I and pharmacologic study of EMD121974, an avP3 and av35 integrin inhibitor that perturbs tumor angiogenesis, in patients with solid tumors. Proc. Am. Soc. Chi]. Oricol. (2000) 19:Abst 801.
   Google Scholar
• COLEMAN PJ, BRASHEAR KM, HUNT CA etal.: Non-peptide av433 antagonists. Part 3: Identification of potent RGD mimetics incorporating novel P-amino acids as aspartic acid replacements. Bioorg. Med. Chem. Lett. (2002) 31–34.
   Google Scholar
• MILLER WH, ALBERTS DP, BHATNAGAR PK et al.: Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic. I Med. Chem. (2000) 43:22–26.
   PubMed Web of Science ®Google Scholar
• LARK MW: Design and characterization of an orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist, SB 265123, for the prevention of bone loss in osteoporosis. j Pharm. Exp. Ther. (1999) 291:612–617.
   PubMed Web of Science ®Google Scholar
• COLEMAN PJ, ASKEW BC, BRASHEAR KM et al.: Design, synthesis, and activity of a new class of chain-shortened non-peptide csP3 receptor antagonists. Abstracts of Papers, 222nd ACS National Meeting, Chicago, IL, USA, August 26–30 (2001) MEDI–191.
   Google Scholar
• COLEMAN PJ, ASKEW BC, BRASHEAR KM et al. Non-peptide a,l33 antagonists. Part 4. Potent and orally bioavailable chain-shortened RGD mimetics, Bioorg. Med. Chem. Lett. (2002) In press.
   Google Scholar